FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis

AL Corneli, J Deese, M Wang, D Taylor… - JAIDS Journal of …, 2014 - journals.lww.com
Background: Several clinical trials have demonstrated the safety and effectiveness of oral
tenofovir disoproxil fumarate (TDF), with or without emtricitabine (FTC), as pre-exposure …

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention

D Donnell, JM Baeten, NN Bumpus… - JAIDS Journal of …, 2014 - journals.lww.com
Background: Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention
strategy for which adherence is a known determinant of efficacy. Blood concentrations of …

Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP

A Corneli, M Wang, K Agot, K Ahmed… - JAIDS Journal of …, 2014 - journals.lww.com
Background: FEM-PrEP was unable to demonstrate the effectiveness of oral
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as pre-exposure prophylaxis for HIV …

Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence

B Hanscom, HE Janes, PD Guarino… - JAIDS Journal of …, 2016 - journals.lww.com
The World Health Organization has issued an early release revision to its antiretroviral
guidelines in which PrEP (pre-exposure prophylaxis in the form of daily oral, fixed dose …

On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a …

G Antoni, C Tremblay, C Delaugerre, I Charreau… - The lancet HIV, 2020 - thelancet.com
Background ANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with
oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative …

[HTML][HTML] Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials

K Agot, D Taylor, AL Corneli, M Wang, J Ambia… - AIDS and Behavior, 2015 - Springer
Oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) has been evaluated as pre-
exposure prophylaxis (PrEP). We describe the accuracy of self-reported adherence to …

Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of …

M Martin, S Vanichseni, P Suntharasamai… - The lancet HIV, 2017 - thelancet.com
Background Results of the randomised, double-blind, placebo-controlled Bangkok Tenofovir
Study (BTS) showed that taking tenofovir daily as pre-exposure prophylaxis (PrEP) can …

PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials

DT Dimitrov, BR Mâsse, D Donnell - JAIDS Journal of Acquired …, 2016 - journals.lww.com
Background: Randomized controlled trials (RCTs) suggest that the efficacy of tenofovir-
based preexposure prophylaxis (PrEP) strongly depends on the consistency of PrEP use …

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence

C Celum, JM Baeten - Current opinion in infectious diseases, 2012 - journals.lww.com
Topical tenofovir gel showed efficacy in African women and daily oral TDF and FTC/TDF
were efficacious in MSM, and African HIV-1 serodiscordant couples and young …

Pre-exposure prophylaxis for HIV prevention in women: current status and future directions

I Hodges-Mameletzis, VA Fonner, S Dalal, N Mugo… - Drugs, 2019 - Springer
Pre-exposure prophylaxis (PrEP) is a promising intervention to prevent HIV acquisition, with
benefits both to the individual and to population-level health. PrEP is an opportunity to …